To expand therapy options, availability, and access, FDA is: Expanding availability and access to evidence-based treatments for substance use disorders Facilitating development of treatments for substance […]

For Immediate Release: July 12, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Wednesday, […]

On This Page Date: March 30 – 31, 2021 Day1: Tue, Mar 30 9:00 AM – 4:30 PM ET Day2: Wed, Mar 31 9:00 AM – […]

Pharmacy Poisons Board of KenyaNational Drug Authority of Uganda FOR IMMEDIATE RELEASEFriday, July 12, 2024 Unprecedented Multilateral Initiative Brings Focus to the Shared Threat Posed by […]

Listen Welcome to the FDA Drug Safety Podcast for health care professionals from the Division of Drug Information. On June 16, 2021, FDA warned that symptoms […]

A U.S. Food and Drug Administration (FDA) review of study findings showed a potential increased risk of heart rhythm problems, called arrhythmias, in patients with heart […]

[Update 7-11-2024] FDA is aware that additional Schwinnng products are being sold in packaging labeled as “On Command” (see image below). These products are being sold […]

On This Page Date: July 11, 2024 Visit CDER Small Business and Industry Assistance Page ABOUT THIS EVENT (Hosted by CDER SBIA) FDA is announcing a […]

The Brief Summary is a quarterly bulletin intended for all Office of Prescription Drug Promotion (OPDP) stakeholders. The Brief Summary provides news and updates related to […]